ReviewCells2017
Stem Cell Therapies in Retinal Disorders.
Review in Cells, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04224207 (Management of Retinitis Pigmentosa by Wharton's Jelly Derived Mesenchymal Stem Cells), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Management of Retinitis Pigmentosa by Wharton's Jelly Derived Mesenchymal Stem Cells: Preliminary Clinical Results
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Early-Phase Clinical Trials of Bio-Artificial Organ Technology: A Systematic Review of Ethical Issues.Transplant international : official journal of the European Society for Organ Transplantation · 2022Pooled it
- Management of retinitis pigmentosa by Wharton's jelly-derived mesenchymal stem cells: prospective analysis of 1-year results.Stem cell research & therapy · 2020Trial
- Management of Retinitis Pigmentosa Via Wharton's Jelly-Derived Mesenchymal Stem Cells or Combination With Magnovision: 3-Year Prospective Results.Stem cells translational medicine · 2023Article
- Treatment of Inherited Retinal Dystrophies with Somatic Cell Therapy Medicinal Product: A Review.Life (Basel, Switzerland) · 2022Review
- Current and Future Treatment of Retinitis Pigmentosa.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Scaffold-Free Retinal Pigment Epithelium Microtissues Exhibit Increased Release of PEDF.International journal of molecular sciences · 2021Article
- Overexpression of pigment epithelium-derived factor in placenta-derived mesenchymal stem cells promotes mitochondrial biogenesis in retinal cells.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- Management of retinitis pigmentosa by Wharton's jelly derived mesenchymal stem cells: preliminary clinical results.Stem cell research & therapy · 2020Article
- Activation of Rod Input in a Model of Retinal Degeneration Reverses Retinal Remodeling and Induces Formation of Functional Synapses and Recovery of Visual Signaling in the Adult Retina.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019Article
- Eye Opener in Stroke.Stroke · 2019Article
- Generation of Retinal Pigmented Epithelium-Like Cells from Pigmented Spheres Differentiated from Bone Marrow Stromal Cell-Derived Neurospheres.Tissue engineering and regenerative medicine · 2019Article
- A new immunodeficient retinal dystrophic rat model for transplantation studies using human-derived cells.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2018Article
- Review
- Autologous stem cell therapy for inherited and acquired retinal disease.Regenerative medicine · 2018Review
- Neuroprotection by (endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases.Current neuropharmacology · 2018Review
- Cell therapy could be a potential way to improve lipoprotein lipase deficiency.Lipids in health and disease · 2017Article
- CRISPR-Cas Genome Surgery in Ophthalmology.Translational vision science & technology · 2017Review
- Assessment of Safety and Functional Efficacy of Stem Cell-Based Therapeutic Approaches Using Retinal Degenerative Animal Models.Stem cells international · 2017Review
- Identification of lncRNAs involved in biological regulation in early age-related macular degeneration.International journal of nanomedicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Stem cell therapy has long been considered a promising mode of treatment for retinal conditions. While human embryonic stem cells (ESCs) have provided the precedent for regenerative medicine, the development of induced pluripotent stem cells (iPSCs) revolutionized this field. iPSCs allow for the development of many types of retinal cells, including those of the retinal pigment epithelium, photoreceptors, and ganglion cells, and can model polygenic diseases such as age-related macular degeneration. Cellular programming and reprogramming technology is especially useful in retinal diseases, as it allows for the study of living cells that have genetic variants that are specific to patients' diseases. Since iPSCs are a self-renewing resource, scientists can experiment with an unlimited number of pluripotent cells to perfect the process of targeted differentiation, transplantation, and more, for personalized medicine. Challenges in the use of stem cells are present from the scientific, ethical, and political realms. These include transplant complications leading to anatomically incorrect placement, concern for tumorigenesis, and incomplete targeting of differentiation leading to contamination by different types of cells. Despite these limitations, human ESCs and iPSCs specific to individual patients can revolutionize the study of retinal disease and may be effective therapies for conditions currently considered incurable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.